Different infliximab induction dosing regimens do not affect remission rates up to 1 year in children with Crohn's disease.

MLA

Marshanski, Tal, et al. “Different Infliximab Induction Dosing Regimens Do Not Affect Remission Rates up to 1 Year in Children with Crohn’s Disease.” Journal of Pediatric Gastroenterology and Nutrition, vol. 79, no. 3, Sept. 2024, pp. 564–72. EBSCOhost, https://doi.org/10.1002/jpn3.12307.

APA

Marshanski, T., Fanous, E., Tal, N., Perets, T. T., Matar, M., Weintraub, Y., Shamir, R., & Shouval, D. S. (2024). Different infliximab induction dosing regimens do not affect remission rates up to 1 year in children with Crohn’s disease. Journal of Pediatric Gastroenterology and Nutrition, 79(3), 564–572. https://doi.org/10.1002/jpn3.12307

Chicago

Marshanski, Tal, Eliana Fanous, Noa Tal, Tsachi T Perets, Manar Matar, Yael Weintraub, Raanan Shamir, and Dror S Shouval. 2024. “Different Infliximab Induction Dosing Regimens Do Not Affect Remission Rates up to 1 Year in Children with Crohn’s Disease.” Journal of Pediatric Gastroenterology and Nutrition 79 (3): 564–72. doi:10.1002/jpn3.12307.